AstraZeneca Diabetes Combo Needs More Clinical Data, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Even though both components are already marketed, firm might have to do another study for fixed-dose combination of DPP-4 inhibitor saxagliptin and SGLT2 inhibitor dapagliflozin.
You may also be interested in...
Keeping Track: US FDA Accepts Ertugliflozin, Extends Reviews Of Abaloparatide, New Keytruda Claim
The latest drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles
The latest drug development news and highlights from our FDA Performance Tracker.
AstraZeneca's Hudson Optimistic On Return To Growth In 2017
US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.